Abstract-Intravenous injection of platelet activating factor (PAF) in anesthetized guinea pigs induces non-selective airway hyperreactivity. This response to PAF was reduced in a dose-dependent manner by systemic administration of established prophylactic anti-asthma drugs (ketotifen, cromoglycate, aminophylline and gluco corticosteroids) and by competitive antagonists of PAF. These inhibitory effects could not be accounted for by antagonism of histamine (H1), serotonin or peptido leukotrienes receptors; parasympatholytic activity; cyclo-oxygenase or lipoxy genase inhibition; mast cell stabilization; or bronchodilatation.
Hyperreactivity of the airways is character istic of asthma and becomes more pro nounced following inhalation of allergen by atopic subjects (1) , respiratory tract infec tions (2) or inhalation of endotoxin (3) . It has been presumed that airway hyperreactivity is a consequence of inflammatory events. Ob struction of the airway lumen by mucosal swelling and impaired mucus clearance fails to account for airway hyperreactivity, which outlasts physical obstruction due to inflam matory events in the airways (i.e., late-onset reactions) by several days (4) . It is now com monly thought that inflammatory mediators released during allergic reactions determine the changed behavior of airway smooth muscle and, by inference, such a mechanism could account for the hyperreactivity when asthma is not associated with allergic events.
Initially, it was presumed that mast cell or basophil activation could account for symp toms of allergic asthma; hence, the search for autacoids with properties that would ac count for asthma symptoms was directed towards products of mast cell activation. However, although histamine, leukotriene C4 or prostaglandin D2 are potent spasmogens of airway smooth muscle, they do not induce persistent airway hyperreactivity in the guinea pig. Moreover, compounds that inhibit mast cell secretion, e.g., bufrolin (5) , fail to in fluence the development of airway hyper reactivity.
More recently, it has been recognized that tivity due to this agent.
Materials and Methods Animals: Male Dunkin-Hartley guinea pigs, 400-500 g body weight, were used for all experiments.
Measurement of lung function: Guinea pigs were anesthetized with phenobarbitone (100 mg/kg, i.p.) and pentobarbitone (30 mg/kg, i.p.) and paralyzed with gallamine (10 mg/kg, i.m.). Animals were ventilated via a tracheal cannula (8 ml/kg, 1 Hz) using a mixture of air and oxygen (50:50, v/v). Ventilation was monitored at the trachea by a pneumotacho graph (type 0000, Fleisch, U.S.A.) connected to a flow transducer (type M P 4514871, Validyne, U.S.A.).
Coincident pressure changes within the thorax were measured directly from a cannula in the thorax, so that the pressure difference between the trachea and thorax could be measured using a dif ferential transducer (type MP 4524, Validyne, U.S.A.) and displayed on a chart recorder (type R41 1, Beckman dynograph recorder, U.S.A.). Blood pressure and heart rate were recorded from the carotid artery using a transducer (type P23Dd, Gould, U.S.A.). Spasmogens and all intravenous bolus in jections of drugs were made in a volume of 0.2 ml into a cannula in the jugular vein, fol lowed by an infusion of 0.9% NaCI (0.3 ml at 1.1 ml/min). From measurements of air-flow and differential pressure, both airway resis tance (RL) and compliance (CdYf) werE calculated (Respiratory mechanics analyzer, model 6, Buxco, U.S.A.) at each respiratory cycle.
Measurement and induction of airway hy perreactivity: Airway reactivity of guinea pig: that had been prepared for measurement of lung function was determined by intravenous injection of bombesin (240 ng/kg), which induced a modest increase in RL. Successive intravenous injections of bombesin (-18C ng/kg) in untreated animals produces an increased airway resistance, whose am plitude increases upon repeated exposure to the peptide. The capacity of peptides to induce increased bronchoconstrictor re sponses precludes the use of a dose-response curve when defining airway hype rreactivity. PAF (600 ng/kg/hr) was then infused in travenously for a period of one hour in a graded fashion (30 ng/kg for 10 min, followed by 120 ng/kg for 20 min, followed by 450 ng/ kg for 30 min) to prevent cardiovascular col lapse. Following infusion of PAF, the lungs of the animal were inflated by increasing the respiratory volume (15 ml/kg) for a period of 5 breaths. Ten minutes after cessation of the infusion, bombesin (240 ng/kg) was in jected i.v., and the increase of RL was re corded. Airway hyperreactivity was expressed as an incremental increase of RL, which was calculated by subtraction of the maximal value of RL induced by bombesin before the PAF infusion from the maximal value of RL induced by bombesin after the PAF infusion.
Administration of drugs: Drugs and an tagonists were given as an intravenous bolus injection one minute prior to the infusion of PAF and at the same dose throughout in fusion of PAF (e.g., (1 :1) indicates a bolus injection of 1 mg/kg of ketotifen before the PAF infusion and 1 mg/kg/hr of ketotifen during infusion of PAF).
Materials: Platelet activating factor (PAF) (1 -0 hexadecyl -2 -0-acetyl -sn-glycero-3 phosphorylcholine) (Novobiochem) was dis solved in ethanol (1 mg/ml) and stored at -18°C as a stock solution . Dilutions of PAF in 0.9% saline containing 0.25% bovine serum albumin (Fluka) were prepared immediately prior to use. Drugs were dissolved in 0.9% saline. Sodium pentobarbitone and pheno barbitone (Siegfried), bombesin (Bachem), histamine dichloride (Fluka) and gallamine (Davis and Geck) were commercial prepara tions. Sodium cromoglycate (Sandoz), (Takeda), hydrocortisone (Sigma) and ibudilast (Kyorin) were dissolved in 10% ethanol and polyethylene glycol; oxatomide (Janssen), ketanserin (Janssen) and aze lastine (Sandoz) were dissolved in 1 % meth ylpyridone and tartaric acid.
Statistical analysis: Significance of the effect of treatments was determined by Student's t-test for unequal numbers of observations. Results PAF-induced airway hyperreactivity: I n untreated animals, intravenous injection of bombesin (240 ng/kg) produced a modest increase of airway resistance. Following in fusion of PAF (600 ng/kg) over a period of one hour, a marked increase of airway resis tance occurred after injection of bombesin (240 ng/kg), indicating the development of airway hyperreactivity (Fig. 1) . Infusion of PAF at a lower dose (300 ng/kg/hr) produced inconsistent data, and infusion of a higher dose (800 ng/kg/hr) induced responses that were not markedly different from that induced by 600 ng/kg/hr.
Prophylactic anti-asthma drugs: Increased airway reactivity induced by PAF was mar kedly diminished when ketotifen (111 mg/kg) was injected prior to, and together with, an infusion of PAF. Inhibition could not be ac counted for by antagonism of the response to bombesin, since the response to bombesin was not diminished when ketotifen was ad ministered after completion of the infusion of PAF (Fig. 1 ) . The inhibitory action of ketotifen Fig. 1 . Representative traces showing the induction of airway resistance (RL) in response to an intra venous bolus injection (B) of bombesin (240 ng/kg), before and after infusion of increasing concen trations of PAF (total dose 600 ng/kg) over a period of one hour. The upper panel shows the enhanced response to bombesin when saline was included during PAF infusion; the middle panel shows the dimin ished response after keiotifen (1 mg/kg/hr) had been infused during exposure to PAF; the lower panel shows that a bolus injection of ketotifen (1 mg,/kg), given upon cessation of the PAF infusion, did not markedly influence the enhanced response to bombesin. was dose-related between 0.1:0.1 and 1 :1 mg/kg (Fig. 2) . The capacity of ketotifen to prevent development of airway hyperreac tivity (15), but not to reverse established airway hyperreactivity (16) (Table 1) .
By the intravenous route, cromoglycate (1:1 and 10:10 mg/kg) also inhibited the development of hyperreactivity in response to infusion of PAF, but cromoglycate was less potent than ketotifen (Table 1 ). Aminophyl line (1:1 and 10:10 mg/kg) shared with ketotifen, cromoglycate and hydrocortisone the capacity to inhibit development of airway hyperreactivity in response to PAF infusion ( Table 1) . Inhibition of the development of airway hyperreactivity by aminophylline cannot be attributed to sustained bronchodila tor actions, in view of the exceedingly short half-life of this drug in the guinea pig.
Amine antagonists and PAF-induced hy perreactivity: Histamine (H1) antagonism is a property of ketotifen (17) , hence clemastine, mepyramine, azelastine and oxatomide have been used to determine whether activation of histamine (H1) receptors contributed to de velopment of hyperreactivity in response to an infusion of PAF. These competitive histamine (H1) receptor antagonists, at doses which strongly inhibit responses to intravenous his tamine, failed to influence the development of hyperreactivity due to an infusion of PAF (Table 2) . Ketotifen is also a modest inhibitor of serotonin responses (17); however, potent serotonin antagonists categorized as 5HT1 (methysergide), 5HT2 (ketanserin) and 5HT3 failed to effect inhibition of the development of hyperreactivity due to an (20) , but treatment with these compounds prior to and during the PAF infusion failed to diminish induction of hyperreactivity.
Ibudilast is a potent leuko triene antagonist with bronchodilator actions (21, 22) ; infusion of this compound achieved an inhibition of development of airway hy perreactivity comparable with that achieved by established anti-asthma drugs (Table 3) . Oxidation by the cyclo-oxygenase pathway represents a limited portion of eicosanoid metabolism; hence a combined inhibitor of QA 208-199 failed to inhibit the development of hyperreac tivity in response to PAF infusion; and in accord with this observation, the lipoxygenase inhibitor (AA-673) also failed to inhibit the development of airway hyperreactivity (Table  3) . By way of contrast, the cyclooxygenase inhibitor indomethacin intensified broncho spasm due to bombesin following PAF in fusion. This observation is consistent with the evidence that indomethacin intensifies airway responses to diverse stimuli in both animals (23) and humans (24) . Bronchodilators and PAF: The capacity of aminophylline to induce relaxation of airway smooth muscle necessitates consideration of substances with non-selective bronchodilator activity. Infusion of (±)isoprenaline, even at high doses (10 ,ug/kg), produced no percep tible inhibition of the increased response to bombesin which follows exposure to PAF. On the contrary, intensification of hyperreac tivity followed co-incident infusion of (±) isoprenaline and PAF. This outcome can be attributed to an action of isoprenaline per se upon the guinea pig airways to cause in creased airway hyperreactivity by a me chanism unrelated to PAF or platelet activation (25) .
In asthma, parasympatholytics can cause a reduction in airway obstruction that is attributed to bronchodilator effects (26) , but SCH-1000 (atrovent) did not diminish the development of hyperreactivity due to infusion of PAF.
Mast cell stabilization and PAF-induced hyperreactivity: One consequence of the con cept that mast cell activity is central to asthma excabation has been the emergence of a suc cession of compounds which inhibit mast cell activation (27) . Tranilast and oxatoride are potent inhibitors of mast cell activation and hence fall into this category. Neither of these compounds inhibited development of hy perreactivity following infusion of PAF (Table  4) . These results are consistent with the lack of efficacy of (±)isoprenaline, a potent inhib itor of mast cell activation in this test system.
Discussion
The concept of prophylaxis in asthma therapy became widely accepted with the introduction of cromoglycate, a drug which lacked bronchodilator or classical anti-inflam matory activities (28) and which was without immediate clinical benefit (29) . Cromoglycate is not absorbed from the gastrointestinal tract, hence administration by inhalation is manda tory. This limitation led to an extensive search for oral prophylactic anti-asthma drugs by many pharmaceutical companies. Almost all compounds identified by this approach have failed in asthma therapy, notwithstanding their potencies as inhibitors of mast cell ac tivation (30). Thus, bufrolin (31), like ox atomide (32), is clearly ineffective in asthma. Nonetheless, the property of mast cell stabili zation, which contributed to anti-allergy ef ficacy, has been emphasized in justifying the use of oxatomide in anti-asthma therapy, and similiar arguments have been extended for tranilast (33) and nedocromil (34) . Ketotifen was also introduced as an anti-asthma therapy on this basis, and because of clinical efficacy, it has become widely established as an oral prophylactic anti-asthma drug. It has none theless become apparent that at therapeutic concentrations, ketotifen is not an inhibitor of the activation of human mast cells in situ or in vitro (35, 36) .
In addition to cromoglycate and ketotifen, two other established anti-asthma drugs may be classified as prophylactic agents by re ference to clinical studies. Thus, in clinical trials, aminophylline has comparable efficacy to cromo ,glycate (37), and when given in travenously in humans, can reduce airway re activity to histamine at doses insufficient to achieve bronchodilatation (38) ; glucocorti costeroids have also been shown to impair development of airway hyperreactivity in al lergic asthma (39) , and both drug categories inhibit the late-onset reaction to allergen (40, 41) . It must be acknowledged that neither line of evidence is conclusive, for the clinical trial that is appropriate to prophylaxis is preven tion of asthma development and progression. Preventative effects can be revealed by study of infants predisposed to asthma by virtue of family history and environmental factors (42) or in adults when an industrial environment induces asthma de novo (43). There is as yet no evidence that either aminophylline or glucocorticosteroids are effective in these circumstances. Nonetheless, the available clinical experience of steroids and amino phylline suggests that both drug categories might share with cromoglycate and ketotifen the ability to suppress some key event in asthma pathology.
The present study reveals that inhibition of the effects of PAF is a property common to those anti-asthma drugs which have been categorized as prophylactic (cromoglycate, ketotifen, aminophylline and glucocorticoster oids) and hence may be predictive of efficacy for novel compounds. Compounds which can be categorized as histamine (H1) antagonists, serotonin antagonists, peptido-leukotriene antagonists, lipoxygenase inhibitors, cyclo oxygenase inhibitors, mast cell stabilizing compounds and bronchodilators have proved to be ineffectual. Of the compounds in troduced recently into asthma therapy, only ibudilast proved effective as an inhibitor of PAF-induced airway hyperreactivity. Since AA-861, FPL-55712, QA 208-199 and AA 673 did not inhibit this reaction to PAF, it cannot be concluded that the inhibitory effect of ibudilast is a consequence of leukotriene antagonism; rather, it is likely that this prop erty of ibudilast reflects an inhibition of the actions of PAF upon airway tissues.
The failure of other compounds to inhibit responses to PAF is not inconsistent with re ports of clinical benefit in allergic asthma, since inhibition of mast cell activation or sup pression of the generation, or action, of smooth muscle spasmogens can be expected to have symptomatic benefit. However, such effects should be regarded as superficial and should not be equated with prophylactic benefit. Confusion between symptomatic and prophylactic benefit has restricted the use of prophylactic drugs in asthma therapy (44). This situation will persist until preventative trials are used to evaluate anti-asthma drugs. Inhibition of PAF-induced pathology can readily be interpreted as a preventative effect, because PAF induces protracted inflammatory events in the lung in which eosinophil ac cumulation and activation are prominent (45). On empirical grounds, therefore, inhibition of PAF-induced hyperreactivity could provide a basis for anti-asthma drug selection. Iden tification of a common site of action of these drugs may be an incisive method for iden tifying key events in asthma pathology.
